• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, November 10, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Machine learning platform guides pancreatic cyst management in patients

Bioengineer by Bioengineer
July 17, 2019
in Cancer
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: S. Springer et al., Science Translational Medicine (2019)

Researchers have created a comprehensive test based on machine learning algorithms to better guide the management of patients with pancreatic cysts – a potential precursor of pancreatic cancer. The new assay, called CompCyst, outperformed the current gold standard-of-care in an international, multicenter study of 875 patients. Crucially, the test would have avoided surgery in 60% of patients who underwent unnecessary surgical removal, suggesting its use could lead to fewer unneeded surgeries and lower health and economic costs. Pancreatic cysts are fluid-filled lesions in the pancreas that are found in up to 8% of all people over the age of 70. Although most cysts are benign, some pancreatic cysts that produce mucin can transform into an aggressive form of pancreatic cancer. What’s more, it is difficult to distinguish precancerous cysts from benign ones, so noncancerous cysts are often misclassified and unnecessarily removed with pancreatic surgery. To overcome this dilemma, Simeon Springer and colleagues enrolled 875 patients with pancreatic cysts and collected information of the mutations, proteins, and other markers linked to their either benign or mucin-producing cysts. They used deep learning techniques to train CompCyst to read these markers and classify patients into those that should be monitored, not monitored, or receive surgery. After training the test protocol with 436 of the original patients, the researchers found the test largely outperformed standard-of-care pathology when evaluated in 426 other patients: it correctly identified 60.4% of patients who should have been discharged (versus 18.9% using standard-of-care diagnosis), 48.6% of patients that should have been monitored (versus 34.3%), and 90.8% of patients in need of surgery (versus 88.8%). Future work will be necessary to prospectively validate the markers used in the test, but Springer et al. say their platform has strong potential to be used in the clinic as a complement to existing approaches.

###

Media Contact
Science Press Package Team
[email protected]

Related Journal Article

http://dx.doi.org/10.1126/scitranslmed.aav4772

Tags: cancerGeneticsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Novel Nerve-Based Prognostic Model for Gastric Cancer

November 10, 2025

Medical and Recreational Cannabis Dispensaries Linked to Decline in Opioid Prescriptions

November 10, 2025

Infertility Treatment Linked to Breast Cancer Risk

November 10, 2025

New Study Reveals How Obesity Drives Breast Cancer Progression

November 10, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    316 shares
    Share 126 Tweet 79
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    207 shares
    Share 83 Tweet 52
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    139 shares
    Share 56 Tweet 35
  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1304 shares
    Share 521 Tweet 326

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Novel Nerve-Based Prognostic Model for Gastric Cancer

Dual Inhibition of Cooperative Motor Proteins Emerges as a Promising Strategy to Kill Cancer Cells

Kazakhstan’s Population Surge: Implications for Healthcare Workforce

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 70 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.